| Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer. VK Morris, CM Parseghian, M Escano, B Johnson, KPS Raghav, A Dasari, ... Journal of Clinical Oncology 40 (4_suppl), 12-12, 2022 | 61 | 2022 |
| Patient-reported out-of-pocket costs and financial toxicity during early-phase oncology clinical trials RW Huey, GC George, P Phillips, R White, S Fu, F Janku, DD Karp, ... The oncologist 26 (7), 588-596, 2021 | 49 | 2021 |
| Cancer chemotherapeutic agents as human teratogens BP Selig, JR Furr, RW Huey, C Moran, VN Alluri, GR Medders, CD Mumm, ... Birth Defects Research Part A: Clinical and Molecular Teratology 94 (8), 626-650, 2012 | 49 | 2012 |
| Survival improvement for patients with metastatic colorectal cancer over twenty years FA Zeineddine, MA Zeineddine, A Yousef, Y Gu, S Chowdhury, A Dasari, ... NPJ Precision Oncology 7 (1), 16, 2023 | 48 | 2023 |
| Mind the gap: Precision oncology and its potential to widen disparities RW Huey, E Hawk, AC Offodile Journal of oncology practice 15 (6), 301-304, 2019 | 39 | 2019 |
| CD28 expression redefines thymocyte development during the pre-T to DP transition TK Teague, C Tan, JH Marino, BK Davis, AA Taylor, RW Huey, ... International immunology 22 (5), 387-397, 2010 | 37 | 2010 |
| Development and validation of a novel nomogram for individualized prediction of survival in cancer of unknown primary K Raghav, H Hwang, AA Jácome, E Bhang, A Willett, RW Huey, ... Clinical Cancer Research 27 (12), 3414-3421, 2021 | 34 | 2021 |
| Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial KP Raghav, B Stephen, DD Karp, SA Piha-Paul, DS Hong, D Jain, ... Journal for immunotherapy of cancer 10 (5), 2022 | 17 | 2022 |
| Bintrafusp alfa, an anti-PD-L1: TGFβ trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer VK Morris, MJ Overman, M Lam, CM Parseghian, B Johnson, A Dasari, ... Cancer research communications 2 (9), 979-986, 2022 | 15 | 2022 |
| Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait RW Huey, S Makawita, L Xiao, A Matamoros, JS Estrella, MJ Overman, ... Bmc Cancer 19, 1-10, 2019 | 15 | 2019 |
| Developing a value framework: utilizing administrative data to assess an enhanced care initiative CJ Allen, JS Eska, NG Thaker, TW Feeley, RS Kaplan, RW Huey, ... Journal of Surgical Research 262, 115-120, 2021 | 11 | 2021 |
| Communicating value: use of a novel framework in the assessment of an enhanced recovery initiative CJ Allen, NG Thaker, L Prakash, BC Kruse, TW Feeley, RS Kaplan, ... Annals of surgery 273 (1), e7-e9, 2021 | 11 | 2021 |
| Antibiotic exposure does not impact immune checkpoint blockade response in MSI-H/dMMR metastatic colorectal cancer: a single-center experience V Serpas Higbie, J Rogers, H Hwang, W Qiao, L Xiao, A Dasari, ... The oncologist 27 (11), 952-957, 2022 | 9 | 2022 |
| Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable (MSS), BRAFV600E metastatic colorectal cancer. VK Morris, CM Parseghian, M Escano, B Johnson, KPS Raghav, A Dasari, ... Journal of Clinical Oncology 40 (16_suppl), 3598-3598, 2022 | 8 | 2022 |
| Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study RW Huey, AT Shah, HV Reddi, P Dasari, JT Topham, H Hwang, N Dhillon, ... JNCI: Journal of the National Cancer Institute 115 (8), 994-997, 2023 | 7 | 2023 |
| Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer. CM Parseghian, E Vilar Sanchez, R Sun, M Eluri, VK Morris, B Johnson, ... Journal of Clinical Oncology 40 (16_suppl), 3520-3520, 2022 | 7 | 2022 |
| Phase II trial of MEDI0457 and durvalumab for patients with recurrent/metastatic HPV-associated cancers. VK Morris, AA Jazaeri, SN Westin, CA Pettaway, S George, R Huey, ... Journal of Clinical Oncology 39 (15_suppl), 2595-2595, 2021 | 7 | 2021 |
| Phase II trial of MEDI0457 and durvalumab for patients with recurrent/metastatic human papillomavirus-associated cancers VK Morris, A Jazaeri, SN Westin, C Pettaway, S George, RW Huey, ... The Oncologist 28 (7), 618-623, 2023 | 5 | 2023 |
| Cancer of Unknown Primary Presenting as Bone‐Predominant or Lymph Node‐Only Disease: A Clinicopathologic Portrait RW Huey, BG Smaglo, JS Estrella, A Matamoros, MJ Overman, ... The Oncologist 26 (4), e650-e657, 2021 | 5 | 2021 |
| Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results … A Dasari, AH Bent, K Alfaro-Munoz, RW Huey, B Johnson, MS Lee, ... Journal of Clinical Oncology 41 (16_suppl), 3522-3522, 2023 | 3 | 2023 |
